Clinical Trial

Endometrial Response in Polycystic Ovarian Syndrome Treated With Letrozole Alone or With Added Estradiol Valerate

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 30, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Polycystic Ovary Syndrome (PCOS) is one of the most common endocrine disorders among women of reproductive age, characterized by chronic anovulation, hyperandrogenism, and polycystic ovarian morphology. Letrozole, an aromatase inhibitor, has emerged as a first-line ovulation induction agent due to its superior ovulation and pregnancy rates compared to clomiphene citrate. Estradiol valerate, a synthetic estrogen, can be co-administered with letrozole to improve endometrial receptivity by enhancing endometrial thickness, vascularity, and pattern. This study aims to evaluate the effect of letrozole alone versus letrozole with estradiol valerate on endometrial development in these patients.
Trial Details
NCT Number NCT07379502
Lead Sponsor CMH Kharian Medical College
Conditions PCOS (Polycystic Ovary Syndrome)
Enrollment 60 participants
Start Date 2026-03-05
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-30